

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 400mg | 360 pills | $0.76 | $323.31 $274.81 Best Price | |
| 400mg | 270 pills | $0.89 | $282.48 $240.11 | |
| 400mg | 180 pills | $1.01 | $213.90 $181.81 | |
| 400mg | 120 pills | $1.15 | $163.28 $138.79 | |
| 400mg | 90 pills | $1.28 | $135.52 $115.19 | |
| 400mg | 60 pills | $1.42 | $99.59 $84.65 | |
| 400mg | 30 pills | $1.62 | $57.14 $48.57 | |
| 800mg | 360 pills | $1.01 | $429.45 $365.03 Popular | |
| 800mg | 270 pills | $1.15 | $365.76 $310.90 | |
| 800mg | 180 pills | $1.28 | $271.05 $230.39 | |
| 800mg | 120 pills | $1.40 | $197.57 $167.93 | |
| 800mg | 90 pills | $1.53 | $161.64 $137.40 | |
| 800mg | 60 pills | $1.67 | $117.56 $99.92 | |
| 800mg | 30 pills | $1.90 | $66.93 $56.89 |
Could Piracetam help with memory problems or cognitive symptoms in adults? Piracetam is a synthetic nootropic used in selected cognitive disorders to support neuronal function and synaptic plasticity, particularly when baseline cognitive performance is affected by aging or neurologic disease. It is not a stimulant, does not have sedative properties, and should be prescribed after a careful evaluation of potential benefits, risks, and patient-specific factors by a qualified clinician.
Piracetam is a cyclic derivative of gamma-aminobutyric acid, but it does not act as a conventional GABA receptor agonist. It belongs to the racetam family and has been investigated for effects on memory, attention, learning, and motor function in diverse clinical settings. The pharmacologic profile emphasizes neural membrane modulation rather than classic neurotransmitter receptor activation.
Available forms include oral tablets in many markets and injectable preparations in others, with dosing tailored to indication and patient factors. It is generally well tolerated and not a cure; the expected benefit is modest and varies with disease severity, comorbidity, and concomitant therapies. Patients should receive appropriate counseling on duration of therapy and expected timelines for response.
Primary indications include cognitive impairment associated with aging or neurodegenerative diseases, where deficits in memory, attention, and processing speed are evident. In such cases, Piracetam is considered as an adjunct to standard care when clinician judgment suggests potential improvement in functional outcomes. Regular reassessment is advised to determine ongoing need and to monitor adverse effects.
Secondary indications include myoclonus, a movement disorder, and rehabilitation after stroke or head injury in selected patients. In these settings, Piracetam is used to support functional recovery and to complement physical and occupational therapy, with expectations discussed with the patient and caregivers. The evidence base remains heterogeneous, and responses are variable across individuals.
Evidence for efficacy varies by condition and patient population, and guidelines differ by region. Clinicians tailor use based on individual risk, prior response, and anticipated benefit, with careful monitoring for adverse effects and interactions. In some patients, alternative or additional therapies may be required to achieve optimal function.
The precise mechanism remains incompletely understood, and no single receptor mediates Piracetamβs action. Piracetam appears to modulate the physical properties of neuronal membranes, promoting fluidity and improved signaling across synapses in various brain regions. These membrane effects may enhance neuronal resilience during cognitive tasks.
Additional effects include enhancement of acetylcholine release in cortical circuits and potential improvements in synaptic plasticity and regional cerebral perfusion. Through these actions, learning processes and post-injury recovery may be supported in select patients, particularly when combined with targeted rehabilitation strategies. The overall pharmacodynamic profile supports a supportive role rather than disease modification in most indications.
Piracetam is generally well tolerated, with a favorable safety profile in many patients. Common adverse events include headaches, insomnia, agitation, dizziness, and gastrointestinal upset, which are typically mild and transient. Patients should report persistent or escalating symptoms to a clinician, particularly if they have preexisting CNS disorders or psychiatric illness.
Renal excretion necessitates dose adjustment in moderate to severe impairment, and patients with renal disease require careful monitoring of efficacy and tolerability. Rare hypersensitivity, rash, dizziness, or allergic reactions can occur; use should be cautious in pregnancy and lactation and in individuals with significant polypharmacy or compromised hepatic function. Ongoing pharmacovigilance and clinician judgment guide safe use in everyday practice.
14β21 days. Free from $200.00 .
5β9 days. $30.00
β10% when paying with cryptocurrency.
β10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
